{"id":"NCT03153137","sponsor":"Actelion","briefTitle":"Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects","officialTitle":"Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-14","primaryCompletion":"2021-06-30","completion":"2021-07-26","firstPosted":"2017-05-15","resultsPosted":"2022-09-13","lastUpdate":"2025-03-30"},"enrollment":142,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Heart Disease"],"interventions":[{"type":"DRUG","name":"Macitentan 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Macitentan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective is to assess the effect of macitentan 10 mg as compared to placebo on exercise capacity through cardiopulmonary exercise testing.","primaryOutcome":{"measure":"Change From Baseline in Peak Oxygen Uptake/Consumption (VO2) Up to Week 16","timeFrame":"Baseline up to Week 16","effectByArm":[{"arm":"Placebo","deltaMin":-0.67,"sd":2.657},{"arm":"Macitentan","deltaMin":-0.16,"sd":2.855}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.1930"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":32,"countries":["United States","Australia","Canada","China","Czechia","Denmark","France","Germany","New Zealand","Poland","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":69},"commonTop":["Headache","Pyrexia","Nasopharyngitis","Abdominal Pain","Upper Respiratory Tract Infection"]}}